Evaluation of the effects of cold atmospheric plasma and plasma-treated liquids in cancer cell cultures.
Por:
Tornin J, Labay C, Tampieri F, Ginebra MP and Canal-Barnils C
Publicada:
1 jun 2021
Ahead of Print:
14 may 2021
Categoría:
Biochemistry, genetics and molecular biology (miscellaneous)
Resumen:
Cold atmospheric plasma (CAP) is a potential anticancer therapy. CAP has cytotoxic effects when applied either directly to cancer cell cultures or indirectly through plasma-conditioned liquids. This protocol describes how to treat adherent cultures of human cancer cell lines with CAP or plasma-conditioned medium and determine cell viability following treatment. The protocol also includes details on how to quantify the reactive oxygen and nitrogen species present in medium following CAP treatment, using chemical probes using UV-visible or fluorescence spectroscopy. CAP treatment takes ~30 min, and 3 h are required to complete quantification of reactive oxygen and nitrogen species. By providing a standardized protocol for evaluation of the effects of CAP and plasma-conditioned medium, we hope to facilitate the comparison and interpretation of results seen across different laboratories.
Filiaciones:
Tornin J:
Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering (CEM), Universitat Politècnica de Catalunya (UPC-BarcelonaTECH), Escola d'Enginyeria Barcelona Est (EEBE), Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Research Center in Biomedical Engineering (CREB), UPC, Barcelona, Spain
Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain
Labay C:
Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering (CEM), Universitat Politècnica de Catalunya (UPC-BarcelonaTECH), Escola d'Enginyeria Barcelona Est (EEBE), Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Research Center in Biomedical Engineering (CREB), UPC, Barcelona, Spain
Tampieri F:
Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering (CEM), Universitat Politècnica de Catalunya (UPC-BarcelonaTECH), Escola d'Enginyeria Barcelona Est (EEBE), Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Research Center in Biomedical Engineering (CREB), UPC, Barcelona, Spain
Ginebra MP:
Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering (CEM), Universitat Politècnica de Catalunya (UPC-BarcelonaTECH), Escola d'Enginyeria Barcelona Est (EEBE), Barcelona, Spain
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain
Research Center in Biomedical Engineering (CREB), UPC, Barcelona, Spain
Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Barcelona, Spain
Canal-Barnils C:
Biomaterials, Biomechanics and Tissue Engineering Group, Department of Materials Science and Engineering (CEM), Universitat Politècnica de Catalunya (UPC-BarcelonaTECH), Escola d'Enginyeria Barcelona Est (EEBE), Barcelona, Spain.
Barcelona Research Center in Multiscale Science and Engineering, UPC, Barcelona, Spain.
Research Center in Biomedical Engineering (CREB), UPC, Barcelona, Spain.
|